|
1
|
Ayers M, Symmans WF, Stec J, Damokosh AI,
Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero
V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN and
Pusztai L: Gene expression profiles predict complete pathologic
response to neoadjuvant paclitaxel and fluorouracil, doxorubicin,
and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol.
22:2284–2293. 2004. View Article : Google Scholar
|
|
2
|
van't Veer LJ, Dai H, van de Vijver MJ, He
YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ,
Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS,
Bernards R and Friend SH: Gene expression profiling predicts
clinical outcome of breast cancer. Nature. 415:530–536.
2002.PubMed/NCBI
|
|
3
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
Organization for Research and Treatment of Cancer, National Cancer
Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I. The value of histological
grade in breast cancer: experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar
|
|
5
|
Asanuma H, Torigoe T, Kamiguchi K,
Hirohashi Y, Ohmura T, Hirata K, Sato M and Sato N: Survivin
expression is regulated by coexpression of human epidermal growth
factor receptor 2 and epidermal growth factor receptor via
phosphatidylinositol 3-kinase/AKT signaling pathway in breast
cancer cells. Cancer Res. 65:11018–11025. 2005. View Article : Google Scholar
|
|
6
|
Petit T, Wilt M, Velten M, Millon R,
Rodier JF, Borel C, Mors R, Haegelé P, Eber M and Ghnassia JP:
Comparative value of tumor grade, hormonal receptors, Ki-67, HER-2
and topoisomerase II alpha status as predictive markers in breast
cancer patients treated with neoadjuvant anthracycline-based
chemotherapy. Eur J Cancer. 40:205–211. 2004. View Article : Google Scholar
|
|
7
|
Fuksa L, Micuda S, Grim J, Ryska A and
Hornychova H: Predictive biomarkers in breast cancer: their value
in neoadjuvant chemotherapy. Cancer Invest. 30:663–678. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cortes J and Roché H: Docetaxel combined
with targeted therapies in metastatic breast cancer. Cancer Treat
Rev. 38:387–396. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Belfiglio M, Fanizza C, Tinari N,
Ficorella C, Iacobelli S and Natoli C: Meta-analysis of phase III
trials of docetaxel alone or in combination with chemotherapy in
metastatic breast cancer. J Cancer Res Clin Oncol. 138:221–229.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nabholtz JM, Falkson C, Campos D, Szanto
J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski
M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A and
Pouillart P: Docetaxel and doxorubicin compared with doxorubicin
and cyclophosphamide as first-line chemotherapy for metastatic
breast cancer: results of a randomized, multicenter, phase III
trial. J Clin Oncol. 21:968–975. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mackey JR, Martin M, Pienkowski T, Rolski
J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T,
Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T,
Rodríguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K,
Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson
V, Rupin M, Houé V and Vogel C: Adjuvant docetaxel, doxorubicin,
and cyclophosphamide in node-positive breast cancer: 10-year
follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol.
14:72–80. 2013.PubMed/NCBI
|
|
12
|
Sachelarie I, Grossbard ML, Chadha M,
Feldman S, Ghesani M and Blum RH: Primary systemic therapy of
breast cancer. Oncologist. 11:574–589. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sánchez-Muñoz A, Plata-Fernández YM,
Fernández M, Jaén-Morago A, Fernández-Navarro M, de la
Torre-Cabrera C, Ramirez-Tortosa C, Lomas-Garrido M, Llácer C,
Navarro-Perez V, Alba-Conejo E and Sánchez-Rovira P: The role of
immunohistochemistry in breast cancer patients treated with
neoadjuvant chemotherapy: an old tool with an enduring prognostic
value. Clin Breast Cancer. 13:146–152. 2013.PubMed/NCBI
|
|
14
|
Untch M, Fasching PA, Konecny GE,
Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A,
Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W,
Mehta KM, von Minckwitz G and Loibl S: Pathologic complete response
after neoadjuvant chemotherapy plus trastuzumab predicts favorable
survival in human epidermal growth factor receptor 2-overexpressing
breast cancer: results from the TECHNO trial of the AGO and GBG
study groups. J Clin Oncol. 29:3351–3357. 2011. View Article : Google Scholar
|
|
15
|
Church DN and Talbot DC: Survivin in solid
tumors: rationale for development of inhibitors. Curr Oncol Rep.
14:120–128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Altieri DC: Survivin, cancer networks and
pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sprenger T, Rodel F, Beissbarth T, Conradi
LC, Rothe H, Homayounfar K, Wolff HA, Ghadimi BM, Yildirim M,
Becker H, Rödel C and Liersch T: Failure of downregulation of
survivin following neoadjuvant radiochemotherapy in rectal cancer
is associated with distant metastases and shortened survival. Clin
Cancer Res. 17:1623–1631. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Petrarca CR, Brunetto AT, Duval V,
Brondani A, Carvalho GP and Garicochea B: Survivin as a predictive
biomarker of complete pathologic response to neoadjuvant
chemotherapy in patients with stage II and stage III breast cancer.
Clin Breast Cancer. 11:129–134. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gerdes J, Schwab U, Lemke H and Stein H:
Production of a mouse monoclonal antibody reactive with a human
nuclear antigen associated with cell proliferation. Int J Cancer.
3:13–20. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Urruticoechea A, Smith IE and Dowsett M:
Proliferation marker Ki-67 in early breast cancer. J Clin Oncol.
23:7212–7220. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
de Azambuja E, Cardoso F, de Castro G Jr,
Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D,
Piccart-Gebhart MJ and Paesmans M: Ki-67 as prognostic marker in
early breast cancer: a meta-analysis of published studies involving
12,155 patients. Br J Cancer. 96:1504–1513. 2007.PubMed/NCBI
|
|
22
|
Stuart-Harris R, Caldas C, Pinder SE and
Pharaoh P: Proliferation markers and survival in early breast
cancer: a systematic review and meta-analysis of 85 studies in
32,825 patients. Breast. 17:323–334. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Colleoni M, Viale G, Zahrieh D,
Bottiglieri L, Gelber RD, Veronesi P, Balduzzi A, Torrisi R, Luini
A, Intra M, Dellapasqua S, Cardillo A, Ghisini R, Peruzzotti G and
Goldhirsch A: Expression of ER, PgR, HER1, HER2, and response: a
study of preoperative chemotherapy. Ann Oncol. 19:465–472. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Colleoni M, Viale G, Zahrieh D, Pruneri G,
Gentilini O, Veronesi P, Gelber RD, Curigliano G, Torrisi R, Luini
A, Intra M, Galimberti V, Renne G, Nolè F, Peruzzotti G and
Goldhirsch A: Chemotherapy is more effective in patients with
breast cancer not expressing steroid hormone receptors: a study of
preoperative treatment. Clin Cancer Res. 10:6622–6628. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang L, Jiang Z, Sui M, Shen J, Xu C and
Fan W: The potential biomarkers in predicting pathologic response
of breast cancer to three different chemotherapy regimens: a case
control study. BMC Cancer. 9:2262009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu C, Yamamoto-Ibusuki M, Yamamoto Y,
Yamamoto S, Fujiwara S, Murakami K, Okumura Y, Yamaguchi L, Fujiki
Y and Iwase H: High survivin mRNA expression is a predictor of poor
prognosis in breast cancer: a comparative study at the mRNA and
protein level. Breast Cancer. Sep 12–2012.(Epub ahead of
print).
|
|
27
|
Lee J, Im YH, Lee SH, Cho EY, Choi YL, Ko
YH, Kim JH, Nam SJ, Kim HJ, Ahn JS, Park YS, Lim HY, Han BK and
Yang JH: Evaluation of ER and Ki-67 proliferation index as
prognostic factors for survival following neoadjuvant chemotherapy
with doxorubicin/docetaxel for locally advanced breast cancer.
Cancer Chemother Pharmacol. 61:569–577. 2008. View Article : Google Scholar
|
|
28
|
Ryan BM, Konecny GE, Kahlert S, Wang HJ,
Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ and
Duffy MJ: Survivin expression in breast cancer predicts clinical
outcome and is associated with HER2, VEGF, urokinase plasminogen
activator and PAI-1. Ann Oncol. 17:597–604. 2006. View Article : Google Scholar : PubMed/NCBI
|
